Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach

被引：0
作者：
Moiso, Enrico [1 ]
Ferraro, Emanuela [1 ]
Cabel, Luc [1 ]
Safonov, Anton [1 ]
Ahmed, Mehnaj [1 ]
An, Julia Ah-Reum [1 ]
Jhaveri, Komal L. [1 ]
Norton, Larry [1 ]
Robson, Mark E. [1 ]
Modi, Shanu [1 ]
Chandarlapaty, Sarat [1 ]
Razavi, Pedram [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1074
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2-Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered
    Pilehvari, Asal
    You, Wen
    Kimmick, Gretchen
    Camacho, Fabian
    Bonilla, Gloribel
    Anderson, Roger
    CLINICAL DRUG INVESTIGATION, 2025, 45 (02) : 59 - 68
  • [32] Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2-metastatic breast cancer
    Abu-Khalaf, Maysa M.
    Hatzis, Christos
    Hodge, K. Alex
    Valdes, Frances
    Sikov, William
    Mita, Monica
    Denduluri, Neelima
    Awerkamp, Kris
    Murphy, Rita
    Zelterman, Daniel
    Dunetz, Bryant
    Petricoin, Emanuel
    Pierobon, Mariaelena
    CANCER RESEARCH, 2021, 81 (04)
  • [33] Composite biomarkers for the prediction of progression-free survival with CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer
    Witkiewicz, Agnieszka
    Wang, Jianxin
    Knudsen, Erik
    Levine, Ellis
    O'Connor, Tracey
    CANCER RESEARCH, 2024, 84 (09)
  • [34] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [35] Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2-metastatic breast cancer
    Abu-Khalaf, Maysa
    Hatzis, Christos
    Hodge, K. Alex
    Baldelli, Elisa
    Sikov, William
    Mita, Monica
    Valdes-Albini, Frances
    Dunetz, Bryant
    Petricoin, Emanuel
    Pierobon, Mariaelena
    CANCER RESEARCH, 2022, 82 (04)
  • [36] Characterizing demographics, clinical, and genomic characteristics for US patients with HR+, HER2-metastatic breast cancer following progression on a CDK4 and 6 inhibitor.
    Andre, Fabrice
    Aggarwal, Amit
    Rao, Xi
    Chen, Yongmei
    Beyrer, Julie Kay
    Smyth, Emily Nash
    Guimaraes, Claudia Morato
    Litchfield, Lacey
    Bowman, Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2-metastatic breast cancer in the United States: A SEER-Medicare population-based study
    Goyal, Ravi K.
    Chen, Hua
    Abughosh, Susan M.
    Holmes, Holly M.
    Candrilli, Sean D.
    Johnson, Michael L.
    CANCER, 2023, 129 (07) : 1051 - 1063
  • [38] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
    Klapp, Vanessa
    Buque, Aitziber
    Bloy, Norma
    Sato, Ai
    Yamazaki, Takahiro
    Zhou, Xi Kathy
    Formenti, Silvia C.
    Galluzzi, Lorenzo
    Petroni, Giulia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [39] Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
    Wu, Sijia
    Xu, Junnan
    Ma, Yiwen
    Liang, Guilian
    Wang, Jiaxing
    Sun, Tao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [40] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
12345